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Background: We investigated whether negative symptoms, such as poor motivation or anhe-
donia, were associated with higher body mass index (BMI) in stable patients with schizophre-
nia chronically treated with antipsychotic medication.   
 
Methods: 62 olanzapine- or clozapine-treated patients with illness duration of at least four 
years were selected from an international multicenter study on the characterization of negative 
symptoms. All participants completed the Brief Negative Symptom Scale (BNSS) and the 
Positive and Negative Syndrome Scale (PANSS). Bivariate correlations between BMI and 
negative symptoms (BNSS) were explored, as well as multiple regression analyses. We further 
explored the association of two principal component factors of the BNSS and BMI. Subsidiary 
analyses re-modeled the above using the negative symptoms subscale of the PANSS and the 
EMSLEY factor for negative symptoms for convergent validity. 
 
Results: Lower negative symptoms (BNSS score) were associated with higher BMI (r=-.31; 
p=.015). A multiple regression analysis showed that negative symptoms (BNSS score) and age 
were significant predictors of BMI (p=0.037). This was mostly driven by the motiva-
tion/pleasure factor of the BNSS. Within this second factor, BMI was negatively associated 
with anhedonia (r=-.254; p=.046) and asociality (r=-.253; p=.048), but not avolition (r=-.169; 
p=.188). EMSLEY score was positively associated with BNSS (r=.873, p<.001), but negative-
ly associated with BMI (r=-.308; p=.015). The association between PANSS and BMI did not 
reach significance (r=-224, p=.080). 
 
Conclusions: We conclude that lower negative symptoms were associated with higher BMI 
(assessed using both the BNSS and EMSLEY) in chronic stable schizophrenia patients, mostly 
due to lower anhedonia and asociality levels.  
 
 























Strategies for preventing weight gain, one concern often reported by individuals receiving 
treatment in the early phases of psychosis, have been partially successful. However, weight 
loss interventions are more limited in chronic schizophrenia compared with other phases of the 
illness and in the general population, despite a higher prevalence of obesity (Royal College of 
Psychiatrists, 2014, Zimbron et al., 2016).  
 
Increased incidence of obesity in schizophrenia has been grossly attributed to antipsychotic 
medication-induced appetite, although a dose-dependent relationship has not been supported 
(Simon et al., 2009). This view contrasts with the multi-factorial approach of obesity applied to 
non-psychiatric populations, which considers a variety of genetic, epigenetic and behavioral 
factors (Ziauddeen et al., 2015). Current models for predicting antipsychotic medication-
induced weight gain are unreliable (Fernandez-Egea et al., 2011) and there remains a need for 
identifying additional factors that might play a significant role in the cause and maintenance of 
weight gain leading to obesity in chronic schizophrenia. Intra-uterine stress (Ziauddeen et al., 
2016) and genetic factors (Reynolds, 2012), for example, have already been shown to have an 
influence. Furthermore, it is likely that obesity in chronic schizophrenia has different predictors 
compared to other phases of the illness, due in part to variations in medication side effects, 
more persistent symptomatology and social consequences of the illness. 
 
Negative symptoms severity has been intuitively associated with greater weight gain (Koga & 
Nakayama, 2005), prompting speculation that problems with motivation underlie physical in-
activity in patients with schizophrenia. However, evidence in support of this is scarce (Janney 
et al., 2013) and has only been provided by studies in populations with medication switching 
(Hermes et al., 2011) and during the onset of the illness (Pérez-Iglesias et al., 2014), when 
changes in psychopathology and body weight are more severe. Understating the role of persis-
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tent negative symptoms in chronic stable patients with schizophrenia may differ from those 
with a recent diagnosis, as antipsychotic medication-induced weight gain is known to plateau 
after three to five years of continuous treatment (Bushe et al., 2013). One study investigating 
weight gain in patients with chronic schizophrenia found that higher negative symptoms were 
associated with lower body mass index (Chen et al., 2014). If more severe negative symptoms 
predict obesity, then behavioural interventions for patients with chronic schizophrenia might be 
more successful if modules for reducing negative symptoms, such as motivation and anhe-
donia, are implemented (e.g. promoting physical exercise; increasing social interaction).  
 
We aimed to test whether high levels of negative symptoms were associated with increased 
body mass index (BMI) in a multi-center international study on the characterization of negative 
symptoms in chronic schizophrenia. We included patients with at least four years of continuous 
prescribed antipsychotic treatment with clozapine or olanzapine, the two leading obesogenic 
antipsychotics (Leucht et al., 2013), in order to reduce medication heterogeneity after the peak 
risk of weight gain. For the assessment of negative symptoms, the Brief Negative Symptoms 
Scale (BNSS) and the Positive and Negative Syndrome Scale (PANSS) were used (both Eng-
lish (Kirkpatrick et al., 2011, Kay et al., 1987) and Spanish (Mané et al., 2014, Peralta & Cues-
ta, 1994) versions). As secondary aims, we explored whether subscales of the BNSS and the 











2. Material and Method 
2.1. Study sample 
The present sample was selected from a multi-centre cross sectional study of the characteriza-
tion of negative symptoms in chronic schizophrenia, which had four primary aims, including 
investigation of the role of negative symptoms in metabolic disease. 
 
The study recruitment dates were May 2015 to May 2016 across four centers, which included 
the Clozapine Clinic at the Cambridgeshire and Peterborough NHS Foundation Trust (Cam-
bridge) and three in Spain: one in Oviedo (Oviedo) and two in Barcelona (Hospital del Mar 
(HMar) and Hospital Clinic (HClinic)). The present study is a continuation of a prior collabora-
tion between sites for the translation and adaptation of the BNSS in Spanish (Mané et al., 
2014), but all cases analyzed here have not been reported elsewhere. All procedures contrib-
uting to this work comply with the ethical standards of the relevant national and institutional 
committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 
2008. 
 
2.2. Inclusion and exclusion criteria 
The multicenter study included patients with a diagnosis of schizophrenia (ICD-10 criteria) at 
any stage of illness. For this particular analysis, we included only those patients who were pre-
scribed with clozapine or olanzapine, the two medications mostly associated with weight gain 
(Leucht et al., 2013a). An additional inclusion criteria was at least four years of antipsychotic 
treatment. All augmentation strategies were allowed, except for clozapine-aripiprazole, as we 
previously reported that this combination is associated with weight loss (Zimbron et al., 2016). 






All participants were evaluated with psychopathology scales as well as morphometric measures 
including a full medical and psychiatric history. The prescribed daily doses of antipsychotic 
medications were converted to an estimated equivalent amount of chlorpromazine in accord-
ance with the international consensus (Gardner et al., 2010). 
 
Morphometric evaluation included measurements of height, weight, diastolic and systolic 
blood pressure and heart rate during resting state. BMI was calculated using the standard for-
mula (BMI= weight (kg) / height 2 (m2)). 
 
Psychopathology scales included the BNSS (Mané et al., 2014, Kirkpatrick et al., 2011) and 
PANSS (Kay et al., 1987, Peralta & Cuesta, 1994), the Calgary Depression Scale (CDS) (Ad-
dington et al., 1990) and cognitive scales, the latter not included in the present study.  To en-
sure interrater reliability between centres, each clinician (a total of five psychiatrists and two 
clinical psychologists) attended a training workshop to learn the administration and scoring of 
all the clinical tools used in the study (BNSS, PANSS and CDS). 
 
2.4. Use of psychopathology scales BNSS and PANSS. 
We used the total BNSS score calculated from all thirteen items (total BNSS). Two major 
components have been defined from this scale (Strauss et al., 2012):  Factor 1 reflects an Emo-
tional Expressivity dimension (PC1 BNSS), consisting of the Blunted Affect, Alogia, and Lack 
of Normal Distress subscales (items 4, 9, 10, 11, 12, 13); and Factor 2 reflects a Motivation 
and Pleasure dimension (PC2 BNSS), consisting of the Anhedonia, Avolition, and Asociality 
subscales (items 1, 2, 3, 5, 6, 7, 8). Some authors have argued that the BNSS comprises three, 
instead of two components (Garcia-Portilla et al., 2015) and that the alogia subscales (items 12 
and 13) should also be considered as an independent component. For the purposes of this 
7 
study, we first used the more widely accepted two components, but also explored the three-
component view for comprehensiveness.  
 
We used items P1 to P7 for the positive symptoms of the PANSS (Pos_PANSS). For negative 
symptoms, we used two different measures: the classical approach (sum of items N1 to N7, 
termed Neg PANSS), and the EMSLEY factor for negative symptoms (sum of items N1, N2, 
N3, N4, N6, GP7 and GP13 and GP16, termed Emsley PANSS (Emsley et al., 2003)). We 
chose these two factors because the PANSS negative subscale (N1 to N7) also contains pure 
cognitive symptoms (i.e. N5 and N6) and is thus less specific to negative symptoms. In addi-
tion, the BNSS and Neg_PANSS are also different measures of negative symptoms. For exam-
ple, Neg_PANSS is based mostly on observed behavior, whereas the BNSS includes internal 
experiences as a factor of negative symptoms severity. 
 
Before the introduction of newer and more valid scales, such as the BNSS, a common practice 
was the use of derived factors, which more accurately captured negative symptoms. In this 
sense, the negative symptoms Emsley PANSS factor includes three items related to avolition 
and associality experiences, and removes two items considered ‘purely cognitive’. 
 
2.5. Statistical analyses 
Zero-order bivariate correlations between total BNSS scores and BMI were explored using 
Person’s correlation. Multiple regression analyses were run with BMI as the dependent varia-
ble and five independent variables including the total BNSS score and four factors that might 
make an independent prediction: gender, age, total antipsychotic equivalent dose and positive 
symptoms total score (Pos_PANSS). These four variables were selected due to gender differ-
ences in the distribution of BMI in the general population and known associations between age, 
medication and weight gain in schizophrenia (Cooper et al., 2016). Severity of positive symp-
toms was also included as patients with more severe symptoms are often treated with higher 
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doses of medication, which has been known to have an association with more secondary nega-
tive symptoms (i.e. sedation or blunted affect) (Kirkpatrick & Galderisi, 2008). 
 
As secondary aims, we explored the prediction of the two primary factors of the BNSS (emo-
tional life and motivation/pleasure) on BMI and whether different measures of negative symp-
toms (PANSS and EMSLEY) provided the same results.  
 
All analyses were performed using SPSS v21.0 for Mac (IBM Inc.) and significance threshold 
was set at p<0.05. 
 
3. Results 
From the initial 134 subjects, 66 were on clozapine or olanzapine treatment. Of those, three 
were excluded due to clozapine-aripiprazole combination. One additional participant (male) 
was excluded due to being overtly underweight, with a BMI score <18, which raised doubts 
about medication compliance. The final sample included 62 volunteers. Participants were re-
cruited from the four participant centers: Cambridge (31), HMar (12), HClinic (11) and Oviedo 
(8). Sample socio-demographic and relevant clinical factors are presented in Table 1. 
 
3.1. Association between BMI and negative symptoms severity (measured with BNSS total 
score) 
Zero-order bivariate correlations showed a significant negative correlation between BMI and 
BNSS (r=-.31; p=.015; Figure 1), such that lower negative symptoms were associated with 
higher BMI. The regression model (Table 2), which accounted for 19% of the variance, was 
significant, F(5,56)=2.57, p=.037. Both negative symptoms (BNSS total score; B=-.37, t=-
2.83, p=.007) and age (B=-.26, t=-2.00, p=.049) significantly predicted BMI. No other variable 




3.2. Association between BMI and BNSS subscales 
Here, we aimed to identify which specific negative symptoms predict BMI. For this set of 
analyses, we used the same model of multiple regression analysis as above, but also included 
Emotional expressivity and Motivation and Pleasure subscales as independent variables (sepa-
rately). Both variables could not be used in the same model, due to the high colinearity be-
tween them (r=.685; p<.001).  
 
As shows Table 2, the first model (including Emotional expressivity) was non-significant 
(p=0.91). However, the second model (including Motivation and Pleasure), which accounted 
for 18% of the variance, was significant F(5,56)=2.43, p=.046. Both motivation/pleasure (B=-
.36, t=-2.71, p=.009) and age (B=-.27, t=-2.09, p=.041) were significant predictors of BMI, 
whereas gender (p=.441), medication equivalents (p=.115) and positive symptoms (p=.933) 
were not.  
 
Specifically, Motivation and Pleasure includes three subscales of negative symptoms: anhe-
donia (items 1, 2, 3), asociality (items 5, 6) and avolition (items 7, 8). Using zero-order bivari-
ate correlations, we found that BMI negatively correlated with anhedonia (r=-.254; p=.046) 
and asociality (r=-.253; p=.048), but not avolition (r=-.169; p=.188), although significance 
levels would not survive when correcting for multiple comparisons.  
 
3.3. Association between BMI and PANSS negative symptoms subscales 
In our sample, the BNSS and Neg_PANSS were highly associated (r=.908, p<.001). However, 
Neg_PANSS and BMI failed to reach significance (r=-.224, p=.080), and a multiple regression 
analysis (using the same variables as above, except with Neg_PANSS as an independent varia-
ble) resulted in a non-significant model (p=.156). Neg_PANSS did not significantly predict 
BMI (p=.055).  
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Emsley PANSS highly correlated with BNSS (r=.873, p<.001) and negatively correlated with 
BMI (r=-.31; p=.014). The multiple regression model using Emsley_PANSS was significant 
F(5,56)=2.52, p=.040, R2=.18) and both Emsley_PANSS (B=-.370, p=.007) and age (B=-.256, 
p=.049) were significant predictors. 
 
3.4. Alternative analyses 
Using patients only treated with clozapine (n=54) or with three BNSS components instead of 
two, the results did not change (data not shown).  
 
We also re-analysed our data using the Peralta and Cuesta’s formula (1994) and found that the 
pattern of results did not change. We found statistical significance between the negative symp-
tom dimension and body mass index (r=-0.30, p=0.02). The multiple regression model using 
this formula was also significant F(5, 56)=2.32, p=0.05, R2=0.17 and the Peralta and Cuesta’s 
factor was a significant predictor of BMI (B=-0.21, p=0.02). 
 
4. Discussion 
Contrary to our initial hypothesis, and other previous studies (Koga & Nakayama, 2005), (Jan-
ney et al., 2013), we found that lower negative symptoms were associated with higher BMI in 
patients with chronic schizophrenia prescribed with either clozapine or olanzapine treatment. 
This was primarily driven by lower anhedonia and asociality levels. This finding, if replicated, 
might be relevant when designing weight control interventions in patients with chronic schizo-
phrenia treated with these medications, and possibly other antipsychotics.  
 
Our study replicates the only study to date reporting that lower levels of negative symptoms are 
associated with higher BMI in chronic schizophrenia patients (Chen et al., 2014). However, 
opposite to previous studies with larger sample sizes (Chen et al., 2014; Gurpegui et al., 2012), 
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we did not find any significant association between BMI and the total scores on the PANSS. 
This is likely due to some confounding factors related to outpatient’s habits, such as exercise, 
lifestyle or economic status (Atmaca et al., 2007). However, our study is the first to use more 
sophisticated measures of negative symptoms, which arguably increases the validity of our 
results. Interestingly, it has been reported that patients under treatment with clozapine or 
olanzapine, the antipsychotics most related with weight gain, have been described to improve 
symptomatology associated with weight gain (Czobor et al., 2002). Noteworthy, our results 
were observed when using the BNSS, and not the commonly used Neg_PANSS score. This 
suggests that a more accurate scale for measuring negative symptoms is required to find these 
associations. Indeed, we aimed to confirm this by using the Emsley PANSS score, which is a 
PANSS scale derivate using a factor analysis, and therefore a more precise score for negative 
symptoms rather than the classical negative subscale from the PANSS. Furthermore, some of 
our results failed to reach significance, but were marginal. Future studies with larger samples 
(and more statistical power) are required to confirm if these effects are present.  
 
We suggest that the role of anhedonia and motivation and their influence on reward processing, 
particularly in related to food rewards, are key factors for interpreting our results. Negative 
symptoms are associated with abnormal reward response (Kirschner et al., 2016) and anhe-
donia severity has been linked to decreased anterior cingulate and medial frontal cortical acti-
vation during task-related motivation (Segarra et al., 2016). Brain mechanisms associated with 
reward have also been studied in metabolic science (Ziauddeen et al., 2015), matching hedonic 
experience and motivation for food. More interestingly, the literature in psychosis has shown 
that enhanced reward activity is associated with higher BMI. Furthermore, a recent study 
showed that drug-naive patients showed higher anticipation during a task of reward activity in 
the right putamen after amisulpride treatment, and experienced greater weight gain (Nielsen et 
al., 2016). To replicate the role of the reward system in weight gain, it has been shown that 
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administering low-dose olanzapine in healthy volunteers (Mathews et al., 2012) enhances re-
ward activity in the dorsal striatum and increases eating behavior.  
 
One possible interpretation is that a preserved hedonic experience in patients with chronic 
schizophrenia could be preventative for losing weight. We previously found that the main de-
terminant of well-being perception in clozapine-treated patients was the presence of positive 
symptoms and not physical health (Brown et al., 2016). A plausible option is that food is a 
widely available reward cue that allows experiencing pleasure in those patients with a pre-
served reward system. Conversely, reduced hedonic experience and poor motivation might be 
linked to less food preparation (i.e. shopping) and eating necessary for intact daily functioning. 
Prioritizing an immediate reward such as food, especially one for the few available in this spe-
cific population over the executive control for delayed reward (i.e. to avoid metabolic compli-
cations to extend lifespan) might hamper successful interventions.  
 
Indeed, in non-scare food environments such as Western countries, overconsumption is thought 
to be driven by a more hedonic form of eating (Zheng & Berthoud, 2008). In mice, separate 
basal ganglia circuitries mediated the hedonic and nutritional actions of sugar (Tellez et al., 
2016). It is also important to note that there is a more limited range of hedonic experiences 
reported by patients with schizophrenia, as social isolation, reduced sex life and unemployment 
are highly prevalent (Generator, 2014). If so, these factors should be taken into account during 
weight intervention strategies as, to date, pharmacological and non pharmacological interven-
tions for weight control in patients with psychosis tend to fail (Speyer et al., 2016) or are of 
little clinical relevance and benefit (Daumit et al., 2013, Zimbron et al., 2016). Therefore, new 
interventions might need to challenge attitudes towards long-term consequences of poor physi-
cal health. If replicated, our results might help better design interventions for patients that 




Our study has some limitations. Firstly, no specific assessments of attitude toward physical 
health or measures of pleasure associated with eating were collected. Secondly, our sample size 
is relatively modest and our results require replication and extension in the same population. 
However, our study was conducted in four different sites in order to avoid sample selection 
bias. Another constraint is the cross-sectional design and the inherent limitation of establishing 
a cause-effect relationship, which warrants further research for understanding the casual role of 
antipsychotic medication on weight gain. Lastly, we did not collect measures of confounding 
factors that are likely related to BMI in schizophrenia. For this reason, more detailed studies 
with larger samples are needed to investigate the possible associations between negative symp-
toms and body mass index taking into account such confounds.  
 
In conclusion, this study explored the prediction of negative symptoms on BMI in patients with 
schizophrenia prescribed with clozapine and/or olanzapine treatment. Our findings suggest that 
less negative symptoms severity, especially lower anhedonia and asociality symptom severity, 
predict increased BMI. These results might help to design more personalized interventions for 
patients with chronic schizophrenia, which could explore the subjective experience of eating or 
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Figure 1. Association between negative symptom severity and BMI.  
 
 
 
 
 
 
 
